nach oben

Rheumatology International

Erschienen in:

01.06.2014 | Short Communication

Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Behçet’s disease

verfasst von: Suhail Aamar, Hagit Peleg, David Leibowitz, Tova Chajek-Shaul, Nurith Hiller, Samuel N. Heyman

Erschienen in: Rheumatology International | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory large-vessel vasculitis in Behçet’s disease may cause life-threatening arterial aneurysms that are prone to rupture. We report a patient with Behçet’s disease with right ventricular thrombus and large aneurysms of the pulmonary arteries that led to recurrent episodes of hemoptysis. Following relapses and only partial response to repeated courses of cyclophosphamide and steroids, the patient was treated with adalimumab (Humira) and is now in clinical remission for over 30 months, with regression of her pulmonary lesions. Anti-TNFα treatment is a potential therapeutic option in patients with life-threatening complications due to large-vessel vasculitis.

Planer D, Leibowitz D, Elitzur Y, Korach A, Hiller N, Chajek-Shaul T (2007) Chronicle of a death foretold: a case of catastrophic vascular Behcet’s disease. Clin Rheumatol 26:457–459PubMedCrossRef

Sfikakis PP (2002) Behcet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):i51–i53

Duzgun N, Ayaslioglu E, Tutkak H, Aydintug OT (2005) Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet’s disease. Rheumatol Int 25:1–5PubMedCrossRef

Leibowitz D, Planer D, Chajek-Shaul T (2007) Echocardiographic manifestations of Adamantiades-Behcet’s disease. Eur J Echocardiogr 8:457–462PubMedCrossRef

Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, Ueda A, Nakamura S, Ohno S, Ishigatsubo Y (2003) Cytokine production profile in patients with Behcet’s disease treated with infliximab. Cytokine 24:210–218PubMedCrossRef

Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP (2003) Mapping the HLA association in Behcet’s disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum 48:807–813PubMedCrossRef

Kamoun M, Chelbi H, Houman MH, Lacheb J, Hamzaoui K (2007) Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet’s disease. Hum Immunol 68:201–205PubMedCrossRef

Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M (2011) Induction of regulatory T cells by infliximab in Behcet’s disease. Invest Ophthalmol Vis Sci 52:476–484PubMedCrossRef

Lee SW, Lee SY, Kim KN, Jung JK, Chung WT (2010) Adalimumab treatment for life threatening pulmonary artery aneurysm in Behcet disease: a case report. Clin Rheumatol 29:91–93PubMedCrossRef

10.

Baki K, Villiger PM, Jenni D, Meyer T, Beer JH (2006) Behcet’s disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis 65:1531–1532PubMedCentralPubMedCrossRef

11.

Adler S, Baumgartner I, Villiger PM (2012) Behcet ‘s disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res 64:607–611CrossRef

12.

Tolosa-Vilella C, Capela CA, Monteagudo-Jiménez M, Marí–Alfonso B (2011) Infliximab for life-threatening pulmonary artery aneurysms in Behcet ‘s disease a case report. Clin Exp Rheumatol 29(Suppl 67):S94–S95PubMed

13.

Lee I, Park S, Hwang I, Kim MJ, Nah SS, Yoo B, Song JK (2008) Cardiac Behcet disease presenting as aortic valvulitis/aortitis or right heart inflammatory mass: a clinicopathologic study of 12 cases. Am J Surg Pathol 32:390–398PubMedCrossRef

14.

Olivieri I, Leccese P, D’Angelo S, Padula A, Nigro A, Palazzi C, Coniglio G, Latanza L (2011) Efficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 29(Suppl 67):S54–S57PubMed

15.

Leccese P, Latanza L, D’Angelo S, Padula A, Olivieri I (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet’s disease to infliximab. Clin Exp Rheumatol 29(Suppl 67):S93PubMed

16.

Leccese P, D’Angelo S, Angela P, Coniglio G, Olivieri I (2010) Switching to adalimumab is effective in a case of neuro-Behcet’s disease refractory to infliximab. Clin Exp Rheumatol 28(Suppl 60):S102PubMed

17.

Atzeni F, Leccese P, D’Angelo S, Sarzi-Puttini P, Olivieri I (2010) Successful treatment of leg ulcers in Behçet’s disease using adalimumab plus methotrexate after the failure of infliximab. Clin Exp Rheumatol 28(Suppl 60):S94PubMed

18.

Olivieri I, D’Angelo S, Padula A, Leccese P, Mennillo GA (2009) Successful treatment of recalcitrant genital ulcers of Behcet’s disease with adalimumab after failure of infliximab and etanercept. Clin Exp Rheumatol 27(Suppl 53):S112PubMed

19.

Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A (2011) Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol 31:165–173PubMedCrossRef

Titel: Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Behçet’s disease
verfasst von: Suhail Aamar
Hagit Peleg
David Leibowitz
Tova Chajek-Shaul
Nurith Hiller
Samuel N. Heyman
Publikationsdatum: 01.06.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 6/2014
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-013-2693-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Behçet’s disease

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

Gastrointestinal manifestations of Behçet’s disease in Japan: a study of 43 patients

The cytospin technique improves the detection of calcium pyrophosphate crystals in synovial fluid samples with a low leukocyte count

IL-32, a potential therapeutic target for rheumatoid arthritis?

Clinical management of patients with hip and knee osteoarthritis: patient satisfaction with treatment switch

Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout

Candidate’s single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin